Analysis of 2017’s top ophthalmology companies by GlobalData has revealed that Eylea (aflibercept) was the driving force behind sales of three out of the five biggest players. The blockbuster biologic—a treatment for wet macular degeneration—is marketed by Regeneron in the US, Santen in Japan, and Bayer AG in the rest of the world, and was estimated by GlobalData to account for 41% of all ophthalmology sales last year.

Top players in ophthalmology, 2017

Source: GlobalData Pharma Intelligence Center

Overall, treatments for wet macular degeneration dominated the ophthalmology portfolios of 2017’s key players. Regeneron was the biggest global player in ophthalmology in 2017, despite its portfolio only consisting of Eylea’s US sales. Lucentis (ranibizumab), another biologic for the treatment of wet macular degeneration, helped propel both Novartis and Roche into third and sixth place, respectively.

Glaucoma drugs were also key components of ophthalmological product portfolios. Sales of Allergan’s Lumigan (bimatoprost) and Alphagan (brimonidine), both topical treatments for glaucoma, helped the company become the second-highest grossing ophthalmology player. Glaucoma drugs were also marketed by Santen, Pfizer, and Valeant—all of which were top-10 ophthalmology players in 2017.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.